Professional Documents
Culture Documents
LOS INHIBIDORES DE LA
BOMBA DE PROTONES
Introduccin:
En
Introduccin:
Conocer
IBPs.
Conocer si existen recomendaciones
previas a la utilizacin del frmaco.
Conocer si deben realizarse controles
rutinarios en los pacientes que precisan
un tratamiento crnico con IBP.
Efectos adversos:
Gastrointestinales:
Diarrea
Estreimiento
Nuseas
Vmitos
Dolor abdominal
Flatulencia.
No gastrointestinales:
Cefalea
Mareo.
Efectos adversos:
A
corto plazo:
Menos frecuentes:
Sequedad de boca
Insomnio
Somnolencia
Malestar general
Visin borrosa
Erupcin
Prurito
Efectos adversos:
Raros
o muy raros:
Disgeusia
Disfuncin heptica.
Edema perifrico
Fotosensibilidad
Fiebre
Sudoracin
Depresin
Nefritis intersticial
Artralgias, mialgias.
Efectos adversos
Raros
o muy raros:
Reacciones de hipersensibilidad:
Angioedema
Urticaria
Broncoespasmo
Anafilaxia
Efectos adversos:
Raros
o muy raros:
Transtornos hemticos:
Leucopenia
Leucocitosis
Pancitopenia
Trombocitopenia.
Efectos adversos:
Raros
o muy raros:
Reacciones cutneas:
Sndrome de Steven-Jonhson
Necrlisis epidrmico-txica
Erupcin ampollosa
Efectos adversos:
Infecciones:
Efectos adversos:
Infecciones
gastrointestinales:
Michael D. Howell, MD, MPH; Victor Novack, MD, PhD; Philip Grgurich, PharmD; Diane Soulliard,
PharmD; Lena Novack, PhD; Michael Pencina, PhD; Daniel Talmor, MD, MPH; Iatrogenic Gastric
Acid Suppression and the Risk of Nosocomial Clostridium difficile Infection; ARCH INTERN
MED/VOL 170 (NO. 9), MAY 10, 2010
Michael D. Howell, MD, MPH; Victor Novack, MD, PhD; Philip Grgurich, PharmD; Diane Soulliard,
PharmD; Lena Novack, PhD; Michael Pencina, PhD; Daniel Talmor, MD, MPH; Iatrogenic Gastric
Acid Suppression and the Risk of Nosocomial Clostridium difficile Infection; ARCH INTERN
MED/VOL 170 (NO. 9), MAY 10, 2010
Michael D. Howell, MD, MPH; Victor Novack, MD, PhD; Philip Grgurich, PharmD; Diane Soulliard,
PharmD; Lena Novack, PhD; Michael Pencina, PhD; Daniel Talmor, MD, MPH; Iatrogenic Gastric
Acid Suppression and the Risk of Nosocomial Clostridium difficile Infection; ARCH INTERN
MED/VOL 170 (NO. 9), MAY 10, 2010
Michael D. Howell, MD, MPH; Victor Novack, MD, PhD; Philip Grgurich, PharmD; Diane Soulliard,
PharmD; Lena Novack, PhD; Michael Pencina, PhD; Daniel Talmor, MD, MPH; Iatrogenic Gastric
Acid Suppression and the Risk of Nosocomial Clostridium difficile Infection; ARCH INTERN
MED/VOL 170 (NO. 9), MAY 10, 2010
Michael D. Howell, MD, MPH; Victor Novack, MD, PhD; Philip Grgurich, PharmD; Diane Soulliard,
PharmD; Lena Novack, PhD; Michael Pencina, PhD; Daniel Talmor, MD, MPH; Iatrogenic Gastric
Acid Suppression and the Risk of Nosocomial Clostridium difficile Infection; ARCH INTERN
MED/VOL 170 (NO. 9), MAY 10, 2010
Michael D. Howell, MD, MPH; Victor Novack, MD, PhD; Philip Grgurich, PharmD; Diane Soulliard,
PharmD; Lena Novack, PhD; Michael Pencina, PhD; Daniel Talmor, MD, MPH; Iatrogenic Gastric
Acid Suppression and the Risk of Nosocomial Clostridium difficile Infection; ARCH INTERN
MED/VOL 170 (NO. 9), MAY 10, 2010
Michael D. Howell, MD, MPH; Victor Novack, MD, PhD; Philip Grgurich, PharmD; Diane Soulliard,
PharmD; Lena Novack, PhD; Michael Pencina, PhD; Daniel Talmor, MD, MPH; Iatrogenic Gastric
Acid Suppression and the Risk of Nosocomial Clostridium difficile Infection; ARCH INTERN
MED/VOL 170 (NO. 9), MAY 10, 2010
Michael D. Howell, MD, MPH; Victor Novack, MD, PhD; Philip Grgurich, PharmD; Diane Soulliard,
PharmD; Lena Novack, PhD; Michael Pencina, PhD; Daniel Talmor, MD, MPH; Iatrogenic Gastric
Acid Suppression and the Risk of Nosocomial Clostridium difficile Infection; ARCH INTERN
MED/VOL 170 (NO. 9), MAY 10, 2010
Michael D. Howell, MD, MPH; Victor Novack, MD, PhD; Philip Grgurich, PharmD; Diane Soulliard,
PharmD; Lena Novack, PhD; Michael Pencina, PhD; Daniel Talmor, MD, MPH; Iatrogenic Gastric
Acid Suppression and the Risk of Nosocomial Clostridium difficile Infection; ARCH INTERN
MED/VOL 170 (NO. 9), MAY 10, 2010
Infecciones gastrointestinales:
Tambin
Campilobacter
Salmonella
Neumona:
Afecta
tanto a:
Neumona:
Monika Sarkar, MD; Sean Hennessy, PharmD, PhD; and Yu-Xiao Yang, MD; Proton-Pump
Inhibitor Use and the Risk for Community-Acquired Pneumonia; Ann Intern Med.
2008;149:391-398.
Neumona:
Monika Sarkar, MD; Sean Hennessy, PharmD, PhD; and Yu-Xiao Yang, MD; Proton-Pump
Inhibitor Use and the Risk for Community-Acquired Pneumonia; Ann Intern Med.
2008;149:391-398.
Neumona:
Monika Sarkar, MD; Sean Hennessy, PharmD, PhD; and Yu-Xiao Yang, MD; Proton-Pump
Inhibitor Use and the Risk for Community-Acquired Pneumonia; Ann Intern Med.
2008;149:391-398.
idiosincrsica
Difcil de predecir
Difcil de diagnosticar
F.SIERRA, M.SUAREZ, M.REY,M.F.VELA; Systematic review: proton pump inhibitorassociated acute interstitial nephritis; Aliment Pharmacol Ther ,2007; 26, 545553
F.SIERRA, M.SUAREZ, M.REY,M.F.VELA; Systematic review: proton pump inhibitorassociated acute interstitial nephritis; Aliment Pharmacol Ther ,2007; 26, 545553
F.SIERRA, M.SUAREZ, M.REY,M.F.VELA; Systematic review: proton pump inhibitorassociated acute interstitial nephritis; Aliment Pharmacol Ther ,2007; 26, 545553
F.SIERRA, M.SUAREZ, M.REY,M.F.VELA; Systematic review: proton pump inhibitorassociated acute interstitial nephritis; Aliment Pharmacol Ther ,2007; 26, 545553
de fracturas de cadera
asociadas a tratamiento prolongado con
IBP.
Alteracin en el metabolismo del calcio
asociado a tratamiento de larga duracin
con IBP.
Tetsuhide Ito and Robert T. Jensen. Association of Long-term Proton Pump Inhibitor Therapy
with bone Fractures and effects on Absorption of Calcium, VitaminB12, Iron, and Magnesium.
Curr Gastroenterol Rep. 2010 December ; 12(6): 448457.
Yang 2006:
Resultados:
Pac en tratamiento con F antisecretores ms de 1 ao presentaba un
aumento del riesgo de fractura de cadera:
IBPs
OR:1,44 95% IC 1.30-1.59
AntiH2
OR:1.23 95% IC 1.09-1.40
IBPs>AntiH2:
OR: 1.34 95% IC 1.14-1.38
>
OR: 1.78 95% IC 95% 1.42-2.22
A ms tiempo de tratamiento y ms alta dosis mayor riesgo de fractura.
Vertergrd, 2006:
Tetsuhide Ito and Robert T. Jensen. Association of Long-term Proton Pump Inhibitor Therapy
with bone Fractures and effects on Absorption of Calcium, VitaminB12, Iron, and Magnesium.
Curr Gastroenterol Rep. 2010 December ; 12(6): 448457.
Vitamina B12:
Desrdenes neurolgicos:
Neuropata
Trastornos de la marcha
Degeneracin espinal
Depresin
Demencia.
Anemia megaloblstica
Tetsuhide Ito and Robert T. Jensen. Association of Long-term Proton Pump Inhibitor Therapy with
bone Fractures and effects on Absorption of Calcium, VitaminB12, Iron, and Magnesium. Curr
Gastroenterol Rep. 2010 December ; 12(6): 448457.
Tetsuhide Ito and Robert T. Jensen. Association of Long-term Proton Pump Inhibitor Therapy
with bone Fractures and effects on Absorption of Calcium, VitaminB12, Iron, and Magnesium.
Curr Gastroenterol Rep. 2010 December ; 12(6): 448457.
Tetsuhide Ito and Robert T. Jensen. Association of Long-term Proton Pump Inhibitor Therapy
with bone Fractures and effects on Absorption of Calcium, VitaminB12, Iron, and Magnesium.
Curr Gastroenterol Rep. 2010 December ; 12(6): 448457.
Vitamina B12:
Ancianos
Pacientes desnutridos.
Tetsuhide Ito and Robert T. Jensen. Association of Long-term Proton Pump Inhibitor Therapy with
bone Fractures and effects on Absorption of Calcium, VitaminB12, Iron, and Magnesium. Curr
Gastroenterol Rep. 2010 December ; 12(6): 448457.
Hierro:
Anemia perniciosa
Aclorhidria
Vagotoma,
Sndrome de zollinger-ellison
Hemocromatosis.
Tetsuhide Ito and Robert T. Jensen. Association of Long-term Proton Pump Inhibitor Therapy with
bone Fractures and effects on Absorption of Calcium, VitaminB12, Iron, and Magnesium. Curr
Gastroenterol Rep. 2010 December ; 12(6): 448457.
Hipomagnesemia:
Fatiga
Inestabilidad
Parestesias
Convulsiones
Tetania
Arritmias cardacas.
Diurticos
Digoxina
Plipos fndicos:
Alan BR Thomson, Michel D Sauve, Narmin Kassam, Holly Kamitakahara; Safety of the long-term use of
proton pump inhibitors;World J Gastroenterol 2010 May 21; 16(19): 2323-2330
Conclusiones: